| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Yoga | 17 | 2022 | 76 | 7.760 |
Why?
|
| Acupuncture Therapy | 13 | 2022 | 89 | 5.760 |
Why?
|
| Quality of Life | 73 | 2024 | 4577 | 5.540 |
Why?
|
| Meditation | 15 | 2023 | 73 | 5.390 |
Why?
|
| Integrative Oncology | 9 | 2024 | 30 | 3.940 |
Why?
|
| Neoplasms | 58 | 2024 | 15204 | 3.610 |
Why?
|
| Stress, Psychological | 26 | 2019 | 996 | 3.530 |
Why?
|
| Sleep Wake Disorders | 14 | 2022 | 350 | 3.250 |
Why?
|
| Caregivers | 12 | 2022 | 680 | 3.230 |
Why?
|
| Complementary Therapies | 14 | 2020 | 126 | 3.050 |
Why?
|
| Xerostomia | 7 | 2022 | 190 | 2.740 |
Why?
|
| Breast Neoplasms | 37 | 2024 | 15710 | 2.600 |
Why?
|
| Fatigue | 18 | 2023 | 1239 | 2.580 |
Why?
|
| Adaptation, Psychological | 23 | 2023 | 763 | 2.450 |
Why?
|
| Depression | 21 | 2023 | 1715 | 2.390 |
Why?
|
| Carcinoma, Renal Cell | 14 | 2022 | 2327 | 2.230 |
Why?
|
| Integrative Medicine | 8 | 2023 | 38 | 2.110 |
Why?
|
| Hot Flashes | 5 | 2020 | 37 | 1.990 |
Why?
|
| Nausea | 6 | 2023 | 525 | 1.860 |
Why?
|
| Survivors | 10 | 2023 | 1035 | 1.830 |
Why?
|
| Qigong | 3 | 2020 | 12 | 1.800 |
Why?
|
| Tai Ji | 3 | 2020 | 17 | 1.780 |
Why?
|
| Peripheral Nervous System Diseases | 4 | 2022 | 393 | 1.670 |
Why?
|
| Mindfulness | 4 | 2020 | 57 | 1.630 |
Why?
|
| Writing | 6 | 2023 | 108 | 1.520 |
Why?
|
| Anxiety | 9 | 2023 | 1189 | 1.450 |
Why?
|
| Antineoplastic Agents | 18 | 2023 | 14302 | 1.410 |
Why?
|
| Middle Aged | 106 | 2024 | 86446 | 1.320 |
Why?
|
| Kidney Neoplasms | 10 | 2022 | 3023 | 1.320 |
Why?
|
| Humans | 176 | 2024 | 262224 | 1.250 |
Why?
|
| Female | 123 | 2024 | 142251 | 1.230 |
Why?
|
| Neurofeedback | 2 | 2018 | 19 | 1.210 |
Why?
|
| Breathing Exercises | 3 | 2021 | 21 | 1.020 |
Why?
|
| Pilot Projects | 13 | 2023 | 2801 | 1.020 |
Why?
|
| Sleep | 7 | 2022 | 414 | 1.000 |
Why?
|
| Electroacupuncture | 3 | 2014 | 35 | 0.970 |
Why?
|
| Exercise | 7 | 2021 | 1186 | 0.960 |
Why?
|
| Communication | 6 | 2016 | 882 | 0.960 |
Why?
|
| Telemedicine | 3 | 2021 | 474 | 0.940 |
Why?
|
| Mind-Body Therapies | 3 | 2020 | 28 | 0.940 |
Why?
|
| Male | 96 | 2024 | 123279 | 0.930 |
Why?
|
| Waiting Lists | 5 | 2017 | 259 | 0.930 |
Why?
|
| Brain-Computer Interfaces | 1 | 2023 | 14 | 0.920 |
Why?
|
| Cross-Cultural Comparison | 3 | 2022 | 87 | 0.920 |
Why?
|
| Acupuncture | 3 | 2020 | 22 | 0.910 |
Why?
|
| Magnesium | 1 | 2024 | 161 | 0.910 |
Why?
|
| Prostatectomy | 4 | 2013 | 963 | 0.900 |
Why?
|
| Spirituality | 7 | 2020 | 128 | 0.900 |
Why?
|
| Actigraphy | 2 | 2020 | 54 | 0.900 |
Why?
|
| Adult | 75 | 2023 | 78088 | 0.890 |
Why?
|
| Hydrocortisone | 5 | 2016 | 389 | 0.890 |
Why?
|
| Aged | 71 | 2024 | 70323 | 0.870 |
Why?
|
| Life Style | 5 | 2024 | 615 | 0.830 |
Why?
|
| Massage | 2 | 2022 | 15 | 0.830 |
Why?
|
| Carcinoma | 5 | 2020 | 2583 | 0.820 |
Why?
|
| Nasopharyngeal Neoplasms | 4 | 2012 | 325 | 0.780 |
Why?
|
| Sexual Partners | 2 | 2018 | 112 | 0.760 |
Why?
|
| Affect | 6 | 2014 | 288 | 0.750 |
Why?
|
| Lung Neoplasms | 9 | 2023 | 11573 | 0.750 |
Why?
|
| Cancer Survivors | 7 | 2024 | 650 | 0.750 |
Why?
|
| Regression Analysis | 8 | 2017 | 1550 | 0.740 |
Why?
|
| Head and Neck Neoplasms | 6 | 2022 | 3978 | 0.740 |
Why?
|
| Vomiting, Anticipatory | 1 | 2020 | 2 | 0.740 |
Why?
|
| Anorexia | 1 | 2021 | 143 | 0.730 |
Why?
|
| Social Support | 11 | 2019 | 560 | 0.730 |
Why?
|
| Electroencephalography | 3 | 2019 | 897 | 0.730 |
Why?
|
| Nursing Care | 1 | 2020 | 13 | 0.720 |
Why?
|
| Biological Products | 1 | 2024 | 298 | 0.720 |
Why?
|
| Neuralgia | 1 | 2023 | 251 | 0.720 |
Why?
|
| Professional-Patient Relations | 1 | 2021 | 129 | 0.700 |
Why?
|
| Hypnosis, Anesthetic | 1 | 2019 | 6 | 0.700 |
Why?
|
| Medicine, Chinese Traditional | 6 | 2020 | 31 | 0.700 |
Why?
|
| Self Report | 6 | 2020 | 766 | 0.680 |
Why?
|
| Vomiting | 2 | 2014 | 354 | 0.680 |
Why?
|
| Physical Therapists | 1 | 2019 | 6 | 0.680 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2019 | 803 | 0.680 |
Why?
|
| Pain Management | 3 | 2013 | 670 | 0.680 |
Why?
|
| Ovarian Neoplasms | 6 | 2024 | 4662 | 0.660 |
Why?
|
| Glioma | 2 | 2022 | 1971 | 0.650 |
Why?
|
| Pain, Postoperative | 6 | 2010 | 619 | 0.650 |
Why?
|
| Radiation Injuries | 2 | 2019 | 1412 | 0.650 |
Why?
|
| Feasibility Studies | 10 | 2021 | 2300 | 0.630 |
Why?
|
| Surveys and Questionnaires | 27 | 2023 | 5714 | 0.630 |
Why?
|
| Pain | 6 | 2023 | 1675 | 0.620 |
Why?
|
| Treatment Outcome | 29 | 2020 | 32991 | 0.620 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2018 | 137 | 0.620 |
Why?
|
| Prostatic Neoplasms | 8 | 2023 | 5777 | 0.610 |
Why?
|
| Medical Oncology | 9 | 2023 | 1425 | 0.600 |
Why?
|
| Spouses | 2 | 2020 | 134 | 0.600 |
Why?
|
| Morphine | 4 | 2008 | 308 | 0.600 |
Why?
|
| Emotions | 4 | 2023 | 567 | 0.580 |
Why?
|
| Analgesia, Patient-Controlled | 3 | 2008 | 59 | 0.570 |
Why?
|
| Expressed Emotion | 1 | 2016 | 21 | 0.560 |
Why?
|
| Oncology Nursing | 3 | 2013 | 51 | 0.540 |
Why?
|
| Exercise Therapy | 1 | 2019 | 291 | 0.540 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 6 | 2023 | 5339 | 0.520 |
Why?
|
| Cognition Disorders | 2 | 2013 | 786 | 0.510 |
Why?
|
| Cluster Analysis | 1 | 2017 | 1055 | 0.510 |
Why?
|
| Mastectomy, Segmental | 2 | 2019 | 1026 | 0.510 |
Why?
|
| CA-125 Antigen | 2 | 2006 | 226 | 0.500 |
Why?
|
| Arthralgia | 1 | 2014 | 96 | 0.470 |
Why?
|
| Alkaline Phosphatase | 1 | 2014 | 208 | 0.470 |
Why?
|
| Physician-Patient Relations | 5 | 2013 | 802 | 0.460 |
Why?
|
| Patient-Centered Care | 2 | 2014 | 298 | 0.460 |
Why?
|
| Antiemetics | 1 | 2014 | 125 | 0.450 |
Why?
|
| Brain | 4 | 2022 | 4113 | 0.450 |
Why?
|
| Cancer Care Facilities | 5 | 2021 | 884 | 0.450 |
Why?
|
| Bayes Theorem | 1 | 2017 | 1032 | 0.450 |
Why?
|
| Behavior Therapy | 2 | 2021 | 295 | 0.440 |
Why?
|
| Amphibian Venoms | 4 | 2015 | 12 | 0.430 |
Why?
|
| Attitude to Health | 4 | 2010 | 466 | 0.430 |
Why?
|
| Neurotransmitter Agents | 1 | 2013 | 160 | 0.420 |
Why?
|
| Hemoglobins | 1 | 2014 | 477 | 0.420 |
Why?
|
| Health Status | 3 | 2006 | 604 | 0.410 |
Why?
|
| Gynecologic Surgical Procedures | 3 | 2005 | 361 | 0.400 |
Why?
|
| Truth Disclosure | 3 | 2005 | 181 | 0.390 |
Why?
|
| Taxoids | 5 | 2017 | 970 | 0.370 |
Why?
|
| Aged, 80 and over | 21 | 2018 | 29997 | 0.370 |
Why?
|
| Preoperative Care | 5 | 2011 | 1529 | 0.360 |
Why?
|
| Mastectomy | 3 | 2010 | 1538 | 0.360 |
Why?
|
| Ileus | 1 | 2010 | 27 | 0.360 |
Why?
|
| Antibody Formation | 1 | 2011 | 383 | 0.350 |
Why?
|
| Interferon-alpha | 2 | 2011 | 889 | 0.350 |
Why?
|
| Preoperative Period | 1 | 2010 | 344 | 0.350 |
Why?
|
| Stress Disorders, Post-Traumatic | 3 | 2015 | 603 | 0.350 |
Why?
|
| Diet | 5 | 2024 | 1451 | 0.350 |
Why?
|
| Cognitive Dysfunction | 1 | 2014 | 332 | 0.350 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 2421 | 0.350 |
Why?
|
| Analgesics, Opioid | 4 | 2008 | 1372 | 0.340 |
Why?
|
| Young Adult | 13 | 2020 | 21474 | 0.340 |
Why?
|
| Cell Proliferation | 4 | 2019 | 7249 | 0.330 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 10 | 2020 | 15874 | 0.330 |
Why?
|
| Indoles | 1 | 2014 | 1011 | 0.330 |
Why?
|
| Radiotherapy | 3 | 2013 | 1826 | 0.320 |
Why?
|
| Carboplatin | 5 | 2024 | 825 | 0.320 |
Why?
|
| Melanoma | 5 | 2021 | 5321 | 0.310 |
Why?
|
| Colectomy | 1 | 2010 | 289 | 0.310 |
Why?
|
| Acupuncture Points | 2 | 2020 | 18 | 0.310 |
Why?
|
| Pain Measurement | 6 | 2018 | 983 | 0.310 |
Why?
|
| Cognition | 1 | 2014 | 975 | 0.300 |
Why?
|
| Cancer Vaccines | 2 | 2002 | 696 | 0.290 |
Why?
|
| Muscle Stretching Exercises | 2 | 2017 | 17 | 0.280 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2015 | 2632 | 0.280 |
Why?
|
| Tibet | 2 | 2022 | 11 | 0.270 |
Why?
|
| Health Behavior | 3 | 2017 | 602 | 0.270 |
Why?
|
| Prospective Studies | 8 | 2024 | 12914 | 0.260 |
Why?
|
| Attitude of Health Personnel | 3 | 2021 | 928 | 0.260 |
Why?
|
| Esophageal Neoplasms | 1 | 2019 | 3170 | 0.260 |
Why?
|
| Prostate-Specific Antigen | 3 | 2011 | 999 | 0.260 |
Why?
|
| China | 2 | 2017 | 611 | 0.260 |
Why?
|
| Mental Health | 6 | 2013 | 409 | 0.260 |
Why?
|
| Evidence-Based Medicine | 4 | 2014 | 1098 | 0.250 |
Why?
|
| Single-Blind Method | 2 | 2018 | 411 | 0.250 |
Why?
|
| Mass Screening | 4 | 2015 | 1505 | 0.250 |
Why?
|
| Physicians | 3 | 2020 | 883 | 0.240 |
Why?
|
| Depressive Disorder | 2 | 2014 | 557 | 0.240 |
Why?
|
| Psilocybin | 1 | 2023 | 5 | 0.240 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2010 | 1218 | 0.230 |
Why?
|
| Defense Mechanisms | 1 | 2003 | 23 | 0.230 |
Why?
|
| Analgesia | 1 | 2004 | 94 | 0.230 |
Why?
|
| United States | 10 | 2024 | 15562 | 0.230 |
Why?
|
| Sick Role | 1 | 2003 | 64 | 0.230 |
Why?
|
| Immunotherapy, Active | 1 | 2003 | 46 | 0.230 |
Why?
|
| Disease Management | 4 | 2019 | 1060 | 0.230 |
Why?
|
| Time Factors | 10 | 2020 | 12968 | 0.230 |
Why?
|
| Agaricales | 1 | 2023 | 11 | 0.230 |
Why?
|
| Laparotomy | 1 | 2004 | 211 | 0.220 |
Why?
|
| Organoplatinum Compounds | 2 | 2017 | 704 | 0.220 |
Why?
|
| Disability Evaluation | 1 | 2004 | 256 | 0.220 |
Why?
|
| Paclitaxel | 4 | 2020 | 1998 | 0.220 |
Why?
|
| Liver Neoplasms | 6 | 2022 | 4561 | 0.220 |
Why?
|
| Politics | 1 | 2023 | 75 | 0.220 |
Why?
|
| Behavioral Medicine | 1 | 2022 | 14 | 0.210 |
Why?
|
| Fluorouracil | 3 | 2017 | 1946 | 0.210 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2017 | 10066 | 0.210 |
Why?
|
| Longitudinal Studies | 3 | 2019 | 1949 | 0.200 |
Why?
|
| Moxibustion | 1 | 2021 | 9 | 0.200 |
Why?
|
| Colonic Neoplasms | 1 | 2010 | 1390 | 0.200 |
Why?
|
| Pituitary-Adrenal System | 1 | 2001 | 97 | 0.200 |
Why?
|
| Lymphoma | 2 | 2014 | 1466 | 0.200 |
Why?
|
| Texas | 8 | 2021 | 6307 | 0.200 |
Why?
|
| Dietary Fiber | 1 | 2021 | 124 | 0.200 |
Why?
|
| Bufanolides | 2 | 2011 | 19 | 0.200 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2001 | 127 | 0.190 |
Why?
|
| Nurse-Patient Relations | 2 | 2016 | 24 | 0.190 |
Why?
|
| Heat-Shock Proteins | 1 | 2002 | 311 | 0.190 |
Why?
|
| Music Therapy | 1 | 2021 | 17 | 0.190 |
Why?
|
| Magnesium Deficiency | 1 | 2020 | 21 | 0.190 |
Why?
|
| Remote Consultation | 1 | 2021 | 37 | 0.190 |
Why?
|
| Videoconferencing | 1 | 2021 | 56 | 0.190 |
Why?
|
| Tumor Microenvironment | 3 | 2022 | 2868 | 0.190 |
Why?
|
| Skin Neoplasms | 3 | 2003 | 4658 | 0.180 |
Why?
|
| Social Adjustment | 2 | 2019 | 114 | 0.180 |
Why?
|
| Health Personnel | 2 | 2021 | 631 | 0.180 |
Why?
|
| Personal Satisfaction | 1 | 2021 | 140 | 0.180 |
Why?
|
| Pancreatic Neoplasms | 3 | 2012 | 5099 | 0.180 |
Why?
|
| Conditioning, Classical | 1 | 2020 | 69 | 0.180 |
Why?
|
| Neoplasm Staging | 6 | 2020 | 13672 | 0.180 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2010 | 1215 | 0.170 |
Why?
|
| Renal Tubular Transport, Inborn Errors | 1 | 2019 | 11 | 0.170 |
Why?
|
| Hypercalciuria | 1 | 2019 | 14 | 0.170 |
Why?
|
| Nephrocalcinosis | 1 | 2019 | 17 | 0.170 |
Why?
|
| Cyclophosphamide | 3 | 2017 | 3002 | 0.170 |
Why?
|
| Osteoradionecrosis | 1 | 2020 | 123 | 0.170 |
Why?
|
| Doxorubicin | 3 | 2017 | 3005 | 0.170 |
Why?
|
| Panax | 2 | 2017 | 34 | 0.170 |
Why?
|
| Qualitative Research | 3 | 2017 | 569 | 0.170 |
Why?
|
| Probiotics | 1 | 2021 | 228 | 0.170 |
Why?
|
| Counseling | 2 | 2019 | 382 | 0.160 |
Why?
|
| A549 Cells | 1 | 2019 | 124 | 0.160 |
Why?
|
| Neoplasm Metastasis | 5 | 2017 | 5121 | 0.160 |
Why?
|
| Anti-Anxiety Agents | 1 | 2019 | 92 | 0.160 |
Why?
|
| Preliminary Data | 1 | 2018 | 12 | 0.160 |
Why?
|
| Cytokines | 3 | 2019 | 2811 | 0.160 |
Why?
|
| Effect Modifier, Epidemiologic | 1 | 2017 | 21 | 0.160 |
Why?
|
| Acetaminophen | 1 | 2019 | 116 | 0.160 |
Why?
|
| Lung | 2 | 2020 | 3157 | 0.160 |
Why?
|
| Patient Satisfaction | 4 | 2013 | 928 | 0.160 |
Why?
|
| Students | 1 | 2000 | 324 | 0.160 |
Why?
|
| Terminal Care | 1 | 2023 | 446 | 0.160 |
Why?
|
| Patient Education as Topic | 4 | 2016 | 757 | 0.150 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 4330 | 0.150 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2019 | 127 | 0.150 |
Why?
|
| Oncologists | 1 | 2020 | 134 | 0.150 |
Why?
|
| Monitoring, Intraoperative | 1 | 2019 | 264 | 0.150 |
Why?
|
| Causality | 1 | 2017 | 178 | 0.150 |
Why?
|
| Musculoskeletal Manipulations | 1 | 2017 | 12 | 0.150 |
Why?
|
| Epirubicin | 1 | 2017 | 157 | 0.150 |
Why?
|
| Follow-Up Studies | 9 | 2019 | 14905 | 0.150 |
Why?
|
| Patient Participation | 1 | 2001 | 462 | 0.150 |
Why?
|
| Platinum Compounds | 1 | 2017 | 131 | 0.140 |
Why?
|
| Religion | 2 | 2020 | 90 | 0.140 |
Why?
|
| Neuropsychological Tests | 2 | 2013 | 1174 | 0.140 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2014 | 2342 | 0.140 |
Why?
|
| Education, Medical | 1 | 2000 | 348 | 0.140 |
Why?
|
| Arachidonate 12-Lipoxygenase | 1 | 2016 | 17 | 0.140 |
Why?
|
| Depressive Disorder, Major | 1 | 2001 | 431 | 0.140 |
Why?
|
| Perception | 1 | 2018 | 353 | 0.140 |
Why?
|
| Dietary Sucrose | 1 | 2016 | 43 | 0.130 |
Why?
|
| Health Education | 1 | 1998 | 309 | 0.130 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2019 | 1417 | 0.130 |
Why?
|
| Referral and Consultation | 3 | 2022 | 899 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2015 | 4943 | 0.130 |
Why?
|
| Cisplatin | 3 | 2020 | 2433 | 0.130 |
Why?
|
| Signal Transduction | 2 | 2016 | 11980 | 0.130 |
Why?
|
| Heel | 1 | 2014 | 10 | 0.130 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2019 | 487 | 0.120 |
Why?
|
| Disease-Free Survival | 5 | 2016 | 10009 | 0.120 |
Why?
|
| Drugs, Chinese Herbal | 2 | 2015 | 58 | 0.120 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2017 | 3891 | 0.120 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 992 | 0.120 |
Why?
|
| Dyssomnias | 1 | 2014 | 7 | 0.120 |
Why?
|
| Cost of Illness | 1 | 2018 | 502 | 0.120 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2019 | 668 | 0.120 |
Why?
|
| Telomere Shortening | 1 | 2014 | 56 | 0.120 |
Why?
|
| Inpatients | 1 | 2020 | 688 | 0.120 |
Why?
|
| Prognosis | 7 | 2020 | 21747 | 0.120 |
Why?
|
| Data Collection | 2 | 2014 | 626 | 0.120 |
Why?
|
| Caspase 3 | 1 | 2015 | 469 | 0.120 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2011 | 2026 | 0.120 |
Why?
|
| Combined Modality Therapy | 5 | 2017 | 8883 | 0.120 |
Why?
|
| Retinoblastoma Protein | 1 | 2015 | 333 | 0.120 |
Why?
|
| Lung Transplantation | 1 | 1998 | 363 | 0.120 |
Why?
|
| Adenocarcinoma | 1 | 2012 | 7793 | 0.120 |
Why?
|
| Serum Albumin | 1 | 2014 | 252 | 0.120 |
Why?
|
| Computers, Handheld | 1 | 2014 | 69 | 0.110 |
Why?
|
| Neurosurgical Procedures | 1 | 2018 | 610 | 0.110 |
Why?
|
| Psychotherapy | 2 | 2023 | 246 | 0.110 |
Why?
|
| Music | 1 | 2013 | 36 | 0.110 |
Why?
|
| Intestinal Pseudo-Obstruction | 1 | 2013 | 39 | 0.110 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 905 | 0.110 |
Why?
|
| Plant Extracts | 1 | 2015 | 224 | 0.110 |
Why?
|
| Saliva | 1 | 2014 | 230 | 0.110 |
Why?
|
| Electrophysiological Phenomena | 1 | 2013 | 75 | 0.110 |
Why?
|
| Anura | 1 | 2012 | 11 | 0.110 |
Why?
|
| DNA Repair | 1 | 2000 | 1871 | 0.110 |
Why?
|
| Patient Compliance | 2 | 2016 | 669 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2015 | 640 | 0.110 |
Why?
|
| Macrophages | 1 | 2019 | 1300 | 0.110 |
Why?
|
| Salivation | 1 | 2012 | 20 | 0.110 |
Why?
|
| Computer Simulation | 1 | 2017 | 1532 | 0.110 |
Why?
|
| Killer Cells, Natural | 2 | 2011 | 904 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2020 | 587 | 0.100 |
Why?
|
| Mammary Glands, Animal | 1 | 2016 | 532 | 0.100 |
Why?
|
| Brain Neoplasms | 2 | 2020 | 4868 | 0.100 |
Why?
|
| Societies, Medical | 1 | 2018 | 1340 | 0.100 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2012 | 70 | 0.100 |
Why?
|
| Risk Factors | 6 | 2017 | 17607 | 0.100 |
Why?
|
| Mood Disorders | 1 | 2013 | 161 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 2 | 2021 | 6916 | 0.100 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2017 | 600 | 0.100 |
Why?
|
| Chemoradiotherapy | 1 | 2020 | 1947 | 0.100 |
Why?
|
| Hyperalgesia | 2 | 2004 | 238 | 0.100 |
Why?
|
| Retrospective Studies | 9 | 2023 | 38010 | 0.100 |
Why?
|
| Fear | 2 | 2023 | 255 | 0.100 |
Why?
|
| Mice | 4 | 2021 | 34442 | 0.100 |
Why?
|
| Animals | 6 | 2021 | 59540 | 0.100 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2012 | 129 | 0.100 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2011 | 701 | 0.100 |
Why?
|
| Observer Variation | 1 | 2013 | 672 | 0.100 |
Why?
|
| Reinforcement Schedule | 1 | 1990 | 26 | 0.090 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 3752 | 0.090 |
Why?
|
| Recombinant Proteins | 3 | 2011 | 2917 | 0.090 |
Why?
|
| Appetitive Behavior | 1 | 1990 | 18 | 0.090 |
Why?
|
| Memory | 2 | 1993 | 429 | 0.090 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2015 | 857 | 0.090 |
Why?
|
| Neuronal Plasticity | 1 | 2013 | 305 | 0.090 |
Why?
|
| Association Learning | 1 | 1990 | 28 | 0.090 |
Why?
|
| Homeopathy | 1 | 2010 | 9 | 0.090 |
Why?
|
| Pyridines | 2 | 2022 | 1245 | 0.090 |
Why?
|
| Remission, Spontaneous | 1 | 2010 | 119 | 0.090 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2013 | 899 | 0.090 |
Why?
|
| Benzenesulfonates | 1 | 2011 | 195 | 0.090 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 2010 | 132 | 0.090 |
Why?
|
| Genital Neoplasms, Female | 1 | 2017 | 741 | 0.090 |
Why?
|
| Defecation | 1 | 2010 | 59 | 0.090 |
Why?
|
| Comprehensive Health Care | 1 | 2010 | 49 | 0.090 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2010 | 51 | 0.090 |
Why?
|
| Life Change Events | 2 | 2004 | 81 | 0.090 |
Why?
|
| Gastrointestinal Motility | 1 | 2010 | 93 | 0.090 |
Why?
|
| Standard of Care | 1 | 2011 | 246 | 0.090 |
Why?
|
| Urologic Neoplasms | 1 | 2011 | 188 | 0.090 |
Why?
|
| Carcinogenesis | 1 | 2016 | 1031 | 0.090 |
Why?
|
| Mental Recall | 1 | 1990 | 172 | 0.090 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 4977 | 0.090 |
Why?
|
| Phytotherapy | 1 | 2010 | 114 | 0.080 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2011 | 363 | 0.080 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2015 | 1039 | 0.080 |
Why?
|
| Postoperative Period | 1 | 2011 | 667 | 0.080 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2011 | 666 | 0.080 |
Why?
|
| Survival Rate | 4 | 2019 | 12236 | 0.080 |
Why?
|
| Decision Making | 2 | 2010 | 1294 | 0.080 |
Why?
|
| Ethanol | 1 | 1990 | 264 | 0.080 |
Why?
|
| Comorbidity | 1 | 2015 | 2394 | 0.080 |
Why?
|
| Risk Assessment | 2 | 2017 | 6891 | 0.080 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2010 | 134 | 0.080 |
Why?
|
| Focus Groups | 1 | 2008 | 259 | 0.080 |
Why?
|
| Cohort Studies | 3 | 2021 | 9293 | 0.080 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2009 | 153 | 0.080 |
Why?
|
| Tongue Neoplasms | 1 | 2009 | 246 | 0.080 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2007 | 104 | 0.080 |
Why?
|
| Glioblastoma | 1 | 2018 | 1810 | 0.070 |
Why?
|
| Double-Blind Method | 3 | 2017 | 2598 | 0.070 |
Why?
|
| Survival Analysis | 2 | 2014 | 9186 | 0.070 |
Why?
|
| Lidocaine | 2 | 2004 | 76 | 0.070 |
Why?
|
| Multivariate Analysis | 4 | 2012 | 4321 | 0.070 |
Why?
|
| Prevalence | 1 | 2015 | 3271 | 0.070 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2008 | 221 | 0.070 |
Why?
|
| Learning | 1 | 1990 | 406 | 0.070 |
Why?
|
| Age Factors | 3 | 2012 | 5386 | 0.070 |
Why?
|
| Deoxycytidine | 1 | 2012 | 1361 | 0.070 |
Why?
|
| Men | 1 | 2006 | 9 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2010 | 1392 | 0.070 |
Why?
|
| Fentanyl | 2 | 2004 | 148 | 0.070 |
Why?
|
| Anesthetics, Local | 2 | 2004 | 163 | 0.070 |
Why?
|
| Recovery of Function | 1 | 2010 | 718 | 0.070 |
Why?
|
| Program Evaluation | 2 | 2008 | 602 | 0.070 |
Why?
|
| Biomarkers | 2 | 2014 | 5049 | 0.070 |
Why?
|
| Patients | 1 | 2008 | 251 | 0.070 |
Why?
|
| Disease Progression | 2 | 2023 | 6695 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 3478 | 0.070 |
Why?
|
| Neoadjuvant Therapy | 2 | 2017 | 4980 | 0.070 |
Why?
|
| Quality of Health Care | 1 | 2010 | 626 | 0.060 |
Why?
|
| Infusions, Intravenous | 1 | 2008 | 1381 | 0.060 |
Why?
|
| Community Health Services | 1 | 2006 | 128 | 0.060 |
Why?
|
| Transcription, Genetic | 1 | 2012 | 3129 | 0.060 |
Why?
|
| Clinical Competence | 2 | 2010 | 1306 | 0.060 |
Why?
|
| Genome, Human | 1 | 2012 | 1866 | 0.060 |
Why?
|
| Trametes | 1 | 2023 | 4 | 0.060 |
Why?
|
| Thinking | 1 | 2003 | 33 | 0.060 |
Why?
|
| Sampling Studies | 1 | 2003 | 170 | 0.060 |
Why?
|
| Avoidance Learning | 1 | 2003 | 94 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2018 | 5565 | 0.050 |
Why?
|
| Patient Care Team | 1 | 2008 | 799 | 0.050 |
Why?
|
| Psychology | 1 | 2003 | 85 | 0.050 |
Why?
|
| Personality Inventory | 1 | 2003 | 178 | 0.050 |
Why?
|
| Multiple Myeloma | 1 | 2014 | 2150 | 0.050 |
Why?
|
| Anesthesia, General | 1 | 2004 | 239 | 0.050 |
Why?
|
| Inflammation | 1 | 2012 | 2515 | 0.050 |
Why?
|
| Analgesia, Epidural | 1 | 2003 | 102 | 0.050 |
Why?
|
| Nurses | 1 | 2003 | 82 | 0.050 |
Why?
|
| Peritoneal Neoplasms | 1 | 2009 | 828 | 0.050 |
Why?
|
| Fatty Acids, Volatile | 1 | 2021 | 52 | 0.050 |
Why?
|
| Test Anxiety Scale | 1 | 2001 | 4 | 0.050 |
Why?
|
| Biomarkers, Tumor | 2 | 2019 | 10356 | 0.050 |
Why?
|
| Demography | 1 | 2003 | 437 | 0.050 |
Why?
|
| Therapeutics | 1 | 2001 | 34 | 0.050 |
Why?
|
| Temperament | 1 | 2001 | 21 | 0.050 |
Why?
|
| Employment | 1 | 2002 | 127 | 0.050 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2021 | 148 | 0.050 |
Why?
|
| Fellowships and Scholarships | 1 | 2005 | 391 | 0.050 |
Why?
|
| Genes, cdc | 1 | 2000 | 80 | 0.050 |
Why?
|
| Symptom Assessment | 1 | 2023 | 271 | 0.050 |
Why?
|
| Educational Status | 1 | 2002 | 396 | 0.050 |
Why?
|
| Cell Line, Tumor | 5 | 2016 | 14594 | 0.050 |
Why?
|
| Erectile Dysfunction | 2 | 2013 | 214 | 0.050 |
Why?
|
| Accelerometry | 1 | 2020 | 63 | 0.050 |
Why?
|
| Residence Characteristics | 1 | 2003 | 349 | 0.050 |
Why?
|
| Psychosocial Support Systems | 1 | 2020 | 7 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 5158 | 0.050 |
Why?
|
| Factor Analysis, Statistical | 1 | 2001 | 357 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 4348 | 0.050 |
Why?
|
| Anilides | 1 | 2022 | 268 | 0.040 |
Why?
|
| Religion and Medicine | 1 | 2020 | 50 | 0.040 |
Why?
|
| Syndrome | 1 | 2023 | 1352 | 0.040 |
Why?
|
| Mammaplasty | 1 | 2007 | 780 | 0.040 |
Why?
|
| Incidence | 2 | 2020 | 5709 | 0.040 |
Why?
|
| Video Recording | 1 | 2021 | 266 | 0.040 |
Why?
|
| Melanoma, Experimental | 1 | 2021 | 368 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2003 | 2311 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2023 | 6036 | 0.040 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2022 | 1249 | 0.040 |
Why?
|
| Empathy | 1 | 2020 | 101 | 0.040 |
Why?
|
| Medicare | 1 | 2024 | 896 | 0.040 |
Why?
|
| Immunotherapy | 2 | 2021 | 3345 | 0.040 |
Why?
|
| DNA Damage | 2 | 2011 | 1955 | 0.040 |
Why?
|
| Psychometrics | 1 | 2023 | 947 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2020 | 233 | 0.040 |
Why?
|
| Nephrectomy | 1 | 2003 | 779 | 0.040 |
Why?
|
| Testosterone | 1 | 2023 | 620 | 0.040 |
Why?
|
| Feces | 1 | 2021 | 772 | 0.040 |
Why?
|
| Motivation | 1 | 2001 | 500 | 0.040 |
Why?
|
| Educational Measurement | 1 | 2000 | 388 | 0.040 |
Why?
|
| Prostate | 1 | 2023 | 1090 | 0.040 |
Why?
|
| Cyclonic Storms | 1 | 2019 | 90 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2003 | 1466 | 0.040 |
Why?
|
| Psychological Tests | 1 | 1998 | 131 | 0.040 |
Why?
|
| Morbidity | 1 | 2018 | 401 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2012 | 3583 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2010 | 5188 | 0.040 |
Why?
|
| DNA Replication | 1 | 2000 | 743 | 0.040 |
Why?
|
| Transfection | 1 | 2000 | 2935 | 0.030 |
Why?
|
| Bone Neoplasms | 1 | 2007 | 2580 | 0.030 |
Why?
|
| Pandemics | 1 | 2024 | 1566 | 0.030 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2015 | 202 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2011 | 3537 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 1748 | 0.030 |
Why?
|
| Random Allocation | 1 | 2016 | 705 | 0.030 |
Why?
|
| Population Surveillance | 1 | 1998 | 628 | 0.030 |
Why?
|
| Health Promotion | 1 | 1998 | 501 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2009 | 5436 | 0.030 |
Why?
|
| Heterografts | 1 | 2016 | 734 | 0.030 |
Why?
|
| Neoplasms, Second Primary | 1 | 2001 | 1351 | 0.030 |
Why?
|
| Adolescent | 4 | 2020 | 31258 | 0.030 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2016 | 494 | 0.030 |
Why?
|
| Bortezomib | 1 | 2014 | 544 | 0.030 |
Why?
|
| Boronic Acids | 1 | 2014 | 363 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2013 | 544 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2002 | 1360 | 0.030 |
Why?
|
| Cardiac Glycosides | 1 | 2011 | 16 | 0.030 |
Why?
|
| Cause of Death | 1 | 2014 | 755 | 0.020 |
Why?
|
| Palliative Care | 1 | 2023 | 2037 | 0.020 |
Why?
|
| Chromones | 1 | 2011 | 120 | 0.020 |
Why?
|
| Taiwan | 1 | 2011 | 93 | 0.020 |
Why?
|
| Pyrazines | 1 | 2014 | 495 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 1999 | 1960 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2011 | 254 | 0.020 |
Why?
|
| Tape Recording | 1 | 2010 | 14 | 0.020 |
Why?
|
| Thalidomide | 1 | 2014 | 569 | 0.020 |
Why?
|
| Hep G2 Cells | 1 | 2010 | 156 | 0.020 |
Why?
|
| Israel | 1 | 2010 | 53 | 0.020 |
Why?
|
| Interferon-gamma | 2 | 2009 | 1143 | 0.020 |
Why?
|
| Phytolacca | 1 | 2010 | 3 | 0.020 |
Why?
|
| Thuja | 1 | 2010 | 3 | 0.020 |
Why?
|
| Conium | 1 | 2010 | 3 | 0.020 |
Why?
|
| Rats, Inbred Strains | 1 | 1990 | 410 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 1990 | 196 | 0.020 |
Why?
|
| Narration | 1 | 2010 | 42 | 0.020 |
Why?
|
| CA-19-9 Antigen | 1 | 2011 | 146 | 0.020 |
Why?
|
| Morpholines | 1 | 2011 | 289 | 0.020 |
Why?
|
| Niacinamide | 1 | 2011 | 421 | 0.020 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2011 | 187 | 0.020 |
Why?
|
| India | 1 | 2010 | 305 | 0.020 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2009 | 83 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2010 | 505 | 0.020 |
Why?
|
| Blood Platelets | 1 | 1994 | 730 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 3861 | 0.020 |
Why?
|
| Apoptosis | 2 | 2015 | 7608 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2010 | 557 | 0.020 |
Why?
|
| Heart Failure | 1 | 2002 | 2523 | 0.020 |
Why?
|
| Cell Separation | 1 | 2010 | 607 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2011 | 1316 | 0.020 |
Why?
|
| Phenylurea Compounds | 1 | 2011 | 581 | 0.020 |
Why?
|
| Castration | 1 | 2007 | 122 | 0.020 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2009 | 409 | 0.020 |
Why?
|
| Hospitalization | 1 | 2017 | 2118 | 0.020 |
Why?
|
| Psychophysiology | 1 | 2007 | 16 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2015 | 8894 | 0.020 |
Why?
|
| Sex Factors | 1 | 2012 | 2156 | 0.020 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2007 | 153 | 0.020 |
Why?
|
| Axilla | 2 | 2000 | 903 | 0.020 |
Why?
|
| Telomere | 1 | 2010 | 507 | 0.020 |
Why?
|
| Placebos | 1 | 2007 | 441 | 0.020 |
Why?
|
| Digital Rectal Examination | 1 | 2006 | 14 | 0.020 |
Why?
|
| Body Image | 1 | 2007 | 141 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2011 | 1906 | 0.020 |
Why?
|
| Patient Simulation | 1 | 2005 | 42 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2010 | 2215 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2010 | 2233 | 0.020 |
Why?
|
| Problem-Based Learning | 1 | 2005 | 80 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2006 | 251 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2010 | 2087 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2011 | 2234 | 0.010 |
Why?
|
| Histones | 1 | 2011 | 1467 | 0.010 |
Why?
|
| Cell Survival | 1 | 2010 | 3047 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2010 | 3024 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2010 | 5387 | 0.010 |
Why?
|
| Imatinib Mesylate | 1 | 2007 | 1665 | 0.010 |
Why?
|
| Intraoperative Period | 1 | 2003 | 246 | 0.010 |
Why?
|
| Education, Nursing | 1 | 2003 | 18 | 0.010 |
Why?
|
| Pain Threshold | 1 | 2003 | 131 | 0.010 |
Why?
|
| Mental Disorders | 1 | 2010 | 867 | 0.010 |
Why?
|
| Physician's Role | 1 | 2005 | 241 | 0.010 |
Why?
|
| Dietary Supplements | 1 | 2007 | 563 | 0.010 |
Why?
|
| Benzamides | 1 | 2007 | 1834 | 0.010 |
Why?
|
| Faculty, Medical | 1 | 2005 | 299 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2009 | 3847 | 0.010 |
Why?
|
| Gene Expression | 1 | 2010 | 3564 | 0.010 |
Why?
|
| Rats | 1 | 1990 | 6109 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2011 | 6105 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2015 | 4770 | 0.010 |
Why?
|
| Phytohemagglutinins | 1 | 1998 | 70 | 0.010 |
Why?
|
| Mitogens | 1 | 1998 | 75 | 0.010 |
Why?
|
| Piperazines | 1 | 2007 | 2100 | 0.010 |
Why?
|
| Physical Fitness | 1 | 1998 | 125 | 0.010 |
Why?
|
| Range of Motion, Articular | 1 | 1999 | 148 | 0.010 |
Why?
|
| Shoulder Joint | 1 | 1999 | 90 | 0.010 |
Why?
|
| Tamoxifen | 1 | 2000 | 876 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2000 | 1364 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 1998 | 481 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1998 | 1489 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2007 | 3536 | 0.010 |
Why?
|
| Catecholamines | 1 | 1994 | 101 | 0.010 |
Why?
|
| Nuclear Reactors | 1 | 1993 | 8 | 0.010 |
Why?
|
| Students, Medical | 1 | 1998 | 418 | 0.010 |
Why?
|
| Photic Stimulation | 1 | 1994 | 261 | 0.010 |
Why?
|
| Models, Psychological | 1 | 1993 | 169 | 0.010 |
Why?
|
| Disasters | 1 | 1993 | 107 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2000 | 4902 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2000 | 4847 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2000 | 2969 | 0.010 |
Why?
|
| Hemodynamics | 1 | 1994 | 941 | 0.010 |
Why?
|
| Chronic Disease | 1 | 1993 | 1837 | 0.000 |
Why?
|